Cantor Fitzgerald Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

Benzinga · 3d ago
Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.